SAPICS’ Post

Health Technology Assessment Unites Nordic Countries: Formation of Joint Nordic HTA-Bodies The formation of the Joint Nordic HTA-Bodies (JNHB) marks a significant advancement in health technology assessment (HTA) collaboration in the Nordic region, now including Denmark and Iceland alongside Finland, Norway, and Sweden. To celebrate, JNHB invited industry associations, decision-makers, and stakeholders to a launch event unveiling their new website, which provides detailed guidance for Health Technology Developers. Initially a grassroots initiative, FINOSE expanded and rebranded to JNHB, formalized through a Memorandum of Understanding signed by the Lægemiddelstyrelsen (Danish Medicines Agency), Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea, Landspítali - The National University Hospital of Iceland, Norwegian Medical Products Agency, and Swedish The Dental and Pharmaceutical Benefits Agency, TLV. For more details please click the link! https://lnkd.in/eUKmdp_a #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

The implementation of the new EU #HTA procedure is currently entering a decisive phase. #MemberStates are drafting and deciding on the detailed rules of the procedure in the “Comitology” Committee on Health Technology Assessment, with the support of the European Commission, which will be laid down in Implementing Acts.   📢 With the other #industry association members of the HTA Stakeholder Network, EUCOPE share serious concerns over the workability of the proposed draft rules, that risk creating an unworkable framework for Joint Clinical Assessments (JCAs) and risk the aim of joint #EU HTA of ensuring better #access for #patients to innovative health technologies.   ❗Unworkable timelines and lack of possibility for early interactions with the assessors mean that especially small to mid-sized companies, that are less resourced, are put under a serious threat of being unable to adequately deliver on their submission and contributing to a #JCA that can fulfil the aim of the Regulation. 👉 Read the joint statement: https://lnkd.in/dDiVT6xv Alliance for Regenerative Medicine, EFPIA - European Federation of Pharmaceutical Industries and Associations, EuropaBio - the European Association for Bioindustries, Vaccines Europe

🌍 Applauding Spain’s New Pharmaceutical Strategy (2024-2028) 🇪🇸 We’re excited to see Spain lead the way with a strategy that prioritizes innovation, access, and social impact in healthcare. 📌 Key Highlights: • Access Guidelines: Developers receiving public funding will follow models ensuring a social return on public investment. • Support for MPP & DNDi: Honoured to see our models promoted in areas of strategic importance like national security and global health. This visionary approach aligns with our work in access and pandemic preparedness, including integrating ‘affordable access plan provisions’ into licensing and funding agreements. We hope to see similar approaches considered by other Member States! 👏 A big step forward—congratulations to all involved! 🔗 Read more: Spanish Pharmaceutical Strategy 2024-2028 https://ow.ly/Qcgv50UtawZ 👉See what MPP is doing in Upstream Access https://ow.ly/Wi6y50Utax0 #PharmaceuticalStrategy #GlobalHealth #AccessToMedicines #Innovation #HealthEquity Drugs for Neglected Diseases initiative - DNDi Javier Padilla

The Spanish Pharmaceutical Industry Strategy includes language on the need to develop equitable access plans, and highlights Medicines Patent Pool and Drugs for Neglected Diseases initiative - DNDi as examples to develop future PPPs in areas of global and national strategic importance. Nada mal Ministerio de Sanidad!

🌍💊 The 59th issue of the IPA CPD e-Times takes you to Bosnia and Herzegovina! Dive into Enisa Salihefendić and Ana Zovko's article exploring: 🔹 The decentralized structure of healthcare 🔹 Pharmacy’s vital role in public health 🔹 Efforts to align with global standards Despite challenges, pharmacists in Bosnia and Herzegovina stand strong as pillars of accessible care. 💙✨ Read more: https://bit.ly/3AL3bHi Indian Pharmaceutical Association || Manjiri Gharat || Raj Vaidya || #IPA #IPA_CPD #59thEtimes #GlobalPharmacy #BosniaPharmacy

In the article "Notre proposition concrète d’un pôle public du médicament" published in September 2023 in Les Cahiers de Santé Publique et de Protection Sociale, a journal edited by the FONDATION GABRIEL PERI, Maryse Montangon, from the Parti Communiste Français (PCF), explains the party's 20-year-old proposal for the creation of a public pharmaceutical hub, conceived as an alternative to detach medications from the financial sphere and turn them into a universal common good. In her words: “It is necessary to reaffirm our country's independence in health matters. The pressure exerted by the markets on the supply of medicines also highlights the need for France to ensure its health sovereignty.” 🔗Check out the full article (in French): https://lnkd.in/djNj5ifm #PPfE #PublicPharma #publicpharmaeurope #publicpharmaforeurope

"Market Access Challenges and Opportunities for #Biosimilars in Latin America," at the upcoming Biosimilars LatAm - Europe 2024 Online Forum on June 19-21. Latin America presents a dynamic landscape for biosimilar #marketaccess. Leading the way, Brazil, Mexico, and Argentina have robust regulatory frameworks but face challenges such as pricing and reimbursement policies. Colombia's tender-based system fosters market competition, while Chile emphasizes cost-effectiveness evaluations. Despite these hurdles, the region offers substantial opportunities for biosimilar penetration, fueled by the increasing demand for affordable biologic therapies and evolving regulatory environments. Featured Speakers: 🔹 Rafael Gual Cosío, General Director at CANIFARMA, Mexico 🔹 Marcela Amaral Pontes, Access Manager at Sindusfarma - Industry Syndicate of Pharmaceutical Products , Brazil 🔹 Moderated by Ignacio Demarco, Commercial Manager LATAM at mAbxience, Argentina Gain insights from industry experts and navigate the complexities of the Latin American biosimilar market. 🔗 Register now to secure your spot! https://lnkd.in/gizVMKtb If you are affiliated with any of the following organizations, reach out for a discount code: 🤝 ABIQUIFI, Asociación Colombiana de Farmacovigilancia, Alianza de CROs de Mexico (ACROM), ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, Asociación de Médicos y Profesionales Especialistas en la Industria Farmacéutica AC, AMELAF, Amepres México, AseBio - Asociación Española de Bioempresas, ASINFAR, Assobiotec, BioSim, CANIFARMA, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, hollandbio, P-BIO - Associação Portuguesa de Bioindústria, PróGenéricos, SEBiot - Sociedad Española de Biotecnología, SINDIFARGO, União Farmacêutica de São Paulo UNIFAR #BiosimilarsLatAm #Europe2024 #Biotech #Innovation #RegulatoryInsights

National Primary Health Care Development Agency (NPHCDA) has collaborated with the National Institute for Pharmaceutical Research and Development (NIPRD) to improve the implementation of evidence-based innovations in the health sector of Nigeria.

While Europe has been the first region to approve and adapt biosimilars, there is still more to be accomplished to democratize access to biologic medicines across the continent. Medicines for Europe’s annual BIOS24 meeting plays a key role in bringing stakeholders who can make a difference together. We believe advancements can be made to:  👉Tailor the clinical development of biosimilars   👉Improve biosimilar guidelines and approval processes  👉Implement sustainable procurement processes that increase competition and secure supply These changes would help keep biosimilars sustainable, which will benefit healthcare systems by providing more affordable treatment options, generating cost savings, and most importantly, granting greater access for patients.    Read more from our experts Isabell Remus, Chair of the Biosimilar medicines sector group at Medicines for Europe & Head Commercial Europe, Sandoz and Martin Schiestl, Global Head Regulatory Affairs Policy, Sandoz.👇 #BIOS24 #Biosimilars #Healthcare https://bit.ly/3JcxZRR

Do you want to discover how biosimilars are revolutionizing healthcare in Brazil? 🧐 Perla Villani Borges, Liana Dalolli, and Marcela Amaral Pontes will be speaking at Biosimilars LatAm - Brazil 2024, sharing insights on how biosimilars are generating significant savings, improving access to treatments, and fostering competition in the pharmaceutical market 💵🏥 Don’t miss this opportunity to learn about the economic benefits of biosimilars and their role in the Brazilian healthcare system in just a few days. 🗓️ Date: August 21-22, 2024 📍 Venue: Pullman Ibirapuera #SãoPaulo Hotel You’re still in time to register and join us for this enriching experience! https://lnkd.in/d5RTHdk2 If you are affiliated with any of the following organizations, please contact us for a discount code: 🤝 ABIFINA, ABIQUIFI, ABRACRO, Alianza de CROs de Mexico (ACROM), ALANAC - Associação dos Laboratórios Farmacêuticos Nacionais, AMELAF, Amepres México, CANIFARMA, CAPGEN - Cámara Argentina de Productores de Medicamentos Hospitalarios, IGBA - International Generic and Biosimilar medicines Association, PróGenéricos, SINDIFARGO, União Farmacêutica de São Paulo - UNIFAR . #BiosimilarsForum #Brazil2024 #CostSavings #MarketDynamics #HealthcareAccess